Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
siRNA innovator ADARx (ADRX.US) launches a $350 million IPO, AbbVie acquires a 4.9% stake and invests up to $100 million

siRNA innovator ADARx (ADRX.US) launches a $350 million IPO, AbbVie acquires a 4.9% stake and invests up to $100 million

智通财经智通财经2026/09/22 07:21
Show original
According to Zhitong Finance APP, ADARx Pharmaceuticals is a biotechnology company in phase 3 clinical trials, developing siRNA therapies for the treatment of multiple diseases. The company announced its IPO terms on Monday.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!